<DOC>
	<DOCNO>NCT01450488</DOCNO>
	<brief_summary>The purpose study evaluate activity oral AB1010 , administer two dose level 3 year patient primary secondary progressive multiple sclerosis .</brief_summary>
	<brief_title>Masitinib Patients With Primary Progressive Multiple Sclerosis ( PPMS ) Relapse-free Secondary Progressive Multiple Sclerosis ( SPMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>1 . Patients age 18 60 year , sex , suffer multiple sclerosis either primary progressive secondary progressive without relapse within 2 year inclusion . 2 . Patients EDSS score range 2 6.5 , inclusive 3 . EDSS progression â‰¥ 1 point within 2 year inclusion 1 . Disease MS responsible clinical sign and/or MRI lesion 2 . Secondary progressive MS relapse 2 year inclusion 3 . Treatment interferon glatiramer acetate within four week prior treatment allocation 4 . Treatment oral systemic corticosteroid ACTH within four week prior treatment allocation . 5 . Active current bacterial , viral ( include hepatitis B C , HIV , EBV , CMV , herpes zoster , herpes simplex ) , fungal , mycobacterium , protozoan , infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>primary progressive multiple sclerosis</keyword>
	<keyword>relapse-free secondary progressive multiple sclerosis</keyword>
</DOC>